Identification of a novel TSC2 c.3610G > A, p.G1204R mutation contribute to aberrant splicing in a patient with classical tuberous sclerosis complex: a case report

Ruixiao Zhang 1,2, Jianhong Wang 3, Qing Wang 4, Yue Han 1,2, Xuejun Liu 5, Irene Bottillo 6, Yanhua Lang 1 and Leping Shao 1,2*

Abstract

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomas in any organ systems. Mutations in the TSC1 or TSC2 gene lead to the dysfunction of hamartin or tuberin proteins, which cause tuberous sclerosis complex.

Case presentation: We describe the clinical characteristics of patients from a Chinese family with tuberous sclerosis complex and analyze the functional consequences of their causal genetic mutations. A novel heterozygous mutation (c.3610G > A) at the last nucleotide of exon 29 in TSC2 was identified. On the protein level, this variant was presumed to be a missense mutation (p.Gly1204Arg). However, the splicing assay revealed that this mutation also leads to the whole TSC2 exon 29 skipping, besides the wild-type transcript. The mutated transcript results in an in-frame deletion of 71 amino acids (p.Gly1133_Thr1203del) and its ratio with the normal splice product is of about 44:56.

Conclusions: The novel c.3610G > A TSC2 mutation was identified in association with tuberous sclerosis complex. And it was proven to code both for a missense-carrying transcript (56%), and for an isoform lacking exon 29 (44%).

Keywords: Tuberous sclerosis complex, TSC1, TSC2, Novel mutation, Aberrant splicing

Background

Tuberous Sclerosis Complex (TSC) is a neurocutaneous disorder with a birth incidence of approximately 1/6,000–1/10,000, and affecting almost 2 million people worldwide [1, 2]. It is characterized by the uncontrolled benign mesenchymal tumor growth in multiple organ systems, including the brain, skin, heart, lung and kidney [3, 4]. The spectrum of clinical manifestation is very wide among individuals due to the different location of the lesions, with combination of symptoms including seizures, developmental delay, intellectual disability, behavioral problems, skin abnormalities, and lung or kidney disease. The differences between gender and races of TSC have not been found, and it will appear at any age ranging from birth to adulthood [5]. TSC is an autosomal-dominantly inherited disorder with high penetrance but variable expressivity, regardless of mutations in either TSC1 or TSC2 gene.

TSC1 and TSC2 respectively code for the hamartin and tuberin proteins, which act as tumor growth suppressors. Hamartin and tuberin interact with each other through their coiled-coil domains to form a stable and functional heterodimer that promotes the GTPase activity of Rheb protein, thus preventing the Rheb-GTP-dependent stimulation of cell proliferation, adhesion, growth, differentiation and migration, through the mTOR pathway [3, 6–8]. Consistent with the Knudson ‘two-hit’ tumor-suppressor gene model [9], a first germline mutation inactivating one allele of either TSC1 or TSC2, and subsequently a somatic event (often loss of heterozygosity) inactivating the second allele, result in
upregulation of the mTOR pathway and lead to overactive cell growth and proliferation [10].

So far, 1,478 different mutations in the TSC genes have been identified to be responsible for the vast majority of cases of TSC according to HGMD (HGMD Professional 2017.4). Herein, we performed clinical and genetic investigation in a Chinese family with classical TSC, and reported the novel heterozygous c.3610G > A, p.G1204R mutation in exon 29 of TSC2 gene. Meanwhile, the effect of this variant in the splicing process was investigated by a mini-gene assay and the RNA analysis.

Case presentation
The pedigree of the family is shown in Fig. 1. The proband (Ib in Fig. 1) was a 47-year-old female of Han Chinese ethnicity (with family from Shandong province, China), who was admitted to our hospital with a chief complaint of “fatigue and chest tightness for 7 days”. She never had a similar episode before. She had neither intellectual disability nor a history of seizures. Her blood pressure was 135/85 mmHg. Physical examination revealed typical facial angiofibromas (adenoma sebaceum) and multiple periungual fibromas (Fig. 2), and obvious abdominal distention. Her biochemical laboratory test demonstrated renal insufficiency (serum creatinine levels: 3.1 mg/dL, normal values 0.5–1.1 mg/dL; estimated glomerular filtration rate: 17.1 ml/min/1.73 m², estimated by CKD-EPI formula) and moderate anemia (hemoglobin of 8.6 g/dL, normal values 11–15 g/dL). Ultrasonography of her both kidneys manifested a heterogeneous mass with a large echogenic fatty component and a less echogenic soft-tissue component with prominent vessels within it, which was suggestive of giant bilateral renal angiomyolipomas (AML) (Fig. 3a). Highly vascular fatty masses were seen on Color Doppler scans (Fig. 3b). Ultrasonography of the left eyes demonstrated a hyperechogenic lesion with posterior shadowing due to calcifications (Fig. 3d). Fundus photograph showed a hamartoma with central calcifications and a surrounding translucent zone in the left eye, suggesting the retinal hamartoma (Fig. 4). Thereafter, non-contrast-enhanced computed tomography (CT) of the abdomen confirmed the ultrasonography diagnosis of giant bilateral renal AMLs with prominent fatty components and internal prominent vessels. Multiple variable-sized air-filled cysts throughout the parenchyma were noted in both lungs consistent with lymphangioleiomyomatosis (LAM) on lung CT. And brain CT revealed multiple calcified subependymal nodules. Images of spine displayed multiple patchy sclerotic lesions (Fig. 5).

Therefore, we considered that the patient fulfilled the diagnostic criteria of TSC [11]. The patient accepted the treatment with the mTOR inhibitor everolimus (10 mg/d) because her AMLs nearly invaded all tissues of bilateral kidneys which could not be removed completely. Two months later, the patient felt a significant alleviation in the feeling of abdominal swelling. Regrettably, she had to discontinue her treatment because of financial difficulties. After half a year follow-up, the patient remained in a stable condition. Besides, she had a son (IIC) who died of epilepsy at the age of six. Her daughter (IIa) also had the presentation of typical facial angiofibromas and multiple periungual fibromas, but she denied further imaging examination. Her husband (Ia) and granddaughter (IIIa) did not show any significant symptoms or abnormalities on testing. To further confirm the diagnosis of TSC, mutation analysis of the TSC1 and TSC2 gene and bioinformatics analysis were performed by the methods in Additional file 1. The CARE guidelines were followed in reporting this case.

By the next generation sequencing, the proband was found to carry a heterozygous guanine to adenine substitution of the last nucleotide in exon 29 of TSC2 (c.3610G > A), resulting in a single amino acid substitution from Glycine to Arginine at amino acid position 1204 (p.Gly1204Arg) (Fig. 6). Sanger sequencing validation of all family members revealed that the proband’s daughter (IIa) carried the same heterozygous p.Gly1204Arg mutation in TSC2 gene, whereas other family members and
100 unrelated controls did not harbor this mutation. No mutation was identified in TSC1 gene.

The c.3610G > A variant was considered as novel since it was neither present in ExAC, 1000G, nor in HGMD databases (HGMD Professional 2017.4). However, another substitution at the same codon (c.3611G > A, p.Gly1204-Glu) has been reported to be related with TSC [12].

The p.Gly1204Arg alteration was predicted as deleterious by three different softwares (i.e. MutationTaster, SIFT and PolyPhen-2). Moreover, the p.Gly1204Arg variant is highly conserved among 8 different species (human, Callorhinchus milii, Macaca mulatta, chimpanzee, house mouse, rat, Xenopus tropicalis and zebrafish) by using Vector NTI Advance 10-Align.

It was noteworthy that the c.3610G > A was a nucleotide substitution at the last position of exon 29, which was located at the upstream close neighbor nucleotide of classical donor splicing site (GT) of intron 29. Therefore, this position may play an important role as splicing modulator. The BDGP and the NetGene2 splice prediction programs were then employed to test whether this mutation could alter the splicing of the TSC2 transcript. Both predictions resulted in the abolishment of the donor splice site. Finally, the in silico analysis by ASSP software showed that the splice donor site strength remarkably decreased from a score of 8.434 to 4.895 (cut off: 4.5).

The mini-gene assay performed to study the effects at the transcript level of the novel c.3610G > A variant showed that the wild-type gave rise to a 476 bp PCR product containing exon 29, the empty pSPL3 control gave rise to a 263 bp PCR fragment missing exon 29 of TSC2 gene. However, the c.3610G > A mutant construct produced two transcripts corresponding to 263 and 476 bp PCR fragments, respectively (Additional file 2: Figure S1). We then investigated whether the mutation c.3610G > A really led to exon 29 skipping in an actual patient. The cDNA was reverse transcribed from total RNA extracted from peripheral blood leucocytes of the proband. By cDNA sequencing, the exon 29-excluded transcript was identified only in the proband and not in a not-mutated individual. Approximately 44% of the cDNA products inserted into the pGEMT Easy vector were missing exon 29, whereas 56% were in-frame.
Discussion and conclusions
In this investigation, by preliminary mutation analysis of TSC gene in this family, a novel heterozygous mutation (c.3610G > A, p.Gly1204Arg) of exon 29 was identified in the TSC2 gene. Predictions by in silico softwares revealed that it could be pathogenic in both protein and mRNA levels. On protein level, the substitution of a small molecular Gly to a more bulky Arg residue at highly conserved position 1204 strongly suggests that this missense mutation is pathogenic. On mRNA level, the results based on the mini-gene splicing assay and the RNA analysis from peripheral blood leucocytes confirmed the deleterious effect of the c.3610G > A alterations on the splicing process, demonstrating that the last nucleotide (c.3610G) of exon 29 in TSC2 gene is an important controller of splicing. The change of guanine to adenine at this position led indeed to a significant decrease in the ability of donor splice site recognition. Above data strongly suggest that the exonic mutation of

![Image](image-url)
c.3610G > A disturbed the normal splicing. The skipping of whole exon 29 is predicted to lead to a defective tuberin with an in-frame deletion of 71 amino acids from p.Gly1133 to p Thr1203 (p.Gly1133_Thr1203del), and a severe impairment of the normal hamartin-tuberin interaction, thus resulting in an upregulation of the mTOR pathway and the generation of TSC. Therefore, with combination of in silico algorithms, in vitro assays and in vivo analyses, an exonic point mutation, which may lead to the disease by both an exon skipping form (accounting for 44%) and a single amino residue alteration (accounting for 56%), was determined in the patients with TSC.

More than half of missense mutations in human are estimated to be the trigger for diseases via affecting the splicing process [13]. For years, only intronic mutations affecting donor or acceptor splice sites (DS or AS) were considered to potentially alter transcriptional processing. This has been questioned as the understanding of splicing mechanisms and concerned splicing signals has

---

**Fig. 5** Non-contrast-enhanced CT Imaging of the proband lb. a. Lung CT scans showing presence of multiple variable sized air filled cysts consistent with lymphangiomyomatosis. b. Abdomen CT scans showing massive bilateral predominantly fatty renal masses consistent with angiomyolipomas. c. Brain CT showing multiple calcified subependymal nodules. d. Spine X-ray showing multiple patchy sclerotic lesions

---

**Fig. 6** TSC2 mutations identified in the proband lb with TSC

---

Wild type

```
| T | G | G | G | G | A | T | C | C |
|---|---|---|---|---|---|---|---|---|
| G | T | A | C | T | G | G | C | C |
| A | G | G | G | C | G | G | C | T |
```

Intron 29

```
| A | E | I | L | V | R | R | P | T |
|---|---|---|---|---|---|---|---|---|
| T | A | C | T | G | G | G | C | T |
| G | G | G | C | G | G | C | T | G |
```

---

c.3610G>A, p.Gly1204Arg

```
| T | G | G | C | G | G | A | T | C | G |
|---|---|---|---|---|---|---|---|---|---|
| G | T | A | C | T | G | G | C | C | A |
| A | G | G | C | G | C | C | A | C | T |
```

Intron 29

```
| A | E | I | L | V | R | R | P | T |
|---|---|---|---|---|---|---|---|---|
| T | A | C | T | G | G | G | C | T |
| G | G | G | C | G | G | C | T | G |
```

---
improved. To our knowledge, the core splicing signals were constitutive of the three motifs (DS, AS and branch point sequence BPS). However, it has been elucidated that the additional signals classified as exonic splicing enhancers (ESEs) or silencers (ESSs), which can promote or inhibit the exon recognition, respectively [14, 15]. In the same way, enhancer (ISE) or silencer (ISS) signals can also be located within introns. In view of the importance of core and auxiliary splicing signals in the pre-mRNA splicing process, it is now recognized that all types of mutations (missense, nonsense as well as small insertions or deletions) can indeed lead to splicing defects either by disrupting or creating signals [16].

In the present family, the proband was characterized by multi-systematic impairment and severe phenotypes, including severe AML of both kidneys, pulmonary LAM and retinal hamartoma. Her son (IIc), a highly suspicious TSC patient, died of epilepsy at the age of 6. Thus, consistent with previous study [7, 12, 17, 18], this family harboring the c.3610G > A TSC2 mutation demonstrated a relatively severe phenotype. Furthermore, this investigation revealed that there was great phenotype variability and different penetrance among TSC patients who share the same mutation of TSC2 gene. The “two-hit” hypothesis, loss of heterozygosity (LOH) or biallelic inactivation caused by a somatic “second-hit” mutation in the other unaffected TSC1 or TSC2 allele on the basis of a heterozygous germline mutation, is an important concept in understanding the variable clinical expression in TSC. However, it was not possible to confirm this hypothesis because we cannot obtain the pathological tissue of this patient. Additionally, modifier genes or other factors may be involved in the phenotype variability of TSC. More recently, some investigations revealed that epigenetic changes, including microRNAs that regulate TSC1 and TSC2 protein expression, may also contribute to phenotype diversity in TSC [19].

In this study, a novel TSC2 missense mutation (c.3610G > A, p.Gly1204Arg), acting both at protein level as a missense alteration (56% of the transcript), and also at mRNA level contributing to exon 29 skipping (44% of the transcript), was identified in a Chinese family with typical TSC. This finding will further expand the TSC mutation database and increase the comprehension of the molecular abnormalities caused by TSC.
Additional files

**Additional file 1:** Materials and methods. A detailed description of the sample acquisition, next generation sequencing (NGS), bioinformatics analyses, multiplex ligation-dependent probe amplification (MLPA), Sanger sequencing, mini-gene constructions expression and RNA analysis. (DOCX 28 kb)

**Additional file 2:** Figure S1. The mini-gene splicing assay based on the pSPL3 exon trapping vector. A. The pSPL3 vector contains the two exons, namely SD and SA, and a functional intron, with transcription beginning following the S440 promoter and ending at the LAP8. Wild pSPL3-W and mutant pSPL3-M plasmids containing 293 bp of intron 28, 213 bp of exon 29 and 352 bp of intron 29 were separately cloned into the XhoI and Nhel cloning sites of the pSPL3 vector. B. Agarose gel electrophoresis of RT-PCR products. SD6 and SA2 primers were designed for RT-PCR amplification of cDNA sequences generated by transfected 293 T cells. Lane 1: marker; Lane 2: 476 bp (263 + 213 bp); Lane 3: empty vector (263 bp); Lane 4: 263 and 476 bp (263 bp + 213 bp). (TIFF 2397 kb)

**Abbreviations**

AML: Angiomyolipoma; AS: Acceptor splicing site; BPS: Branch point sequence; DS: Donor splicing site; ESEs: Exonic splicing enhancers; ESSs: Exonic splicing silencers; GTase: Guanosine triphosphatase; ISE: Intronic splicing enhancer; ISS: Intronic splicing silencer; LAM: Lymphangioleiomyomatosis; mTORC1: mechanistic target of rapamycin complex; Rheb: Ras homolog enriched in brain; TSC: Tuberous sclerosis complex

**Acknowledgements**

We are grateful to all subjects for their participation in this research.

**Funding**

This study was supported by grants from the Natural Science Foundation of China (81707653) and the Shandong Provincial Natural Science Foundation (ZR2014L054).

**Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its Additional files].

**Authors’ contributions**

L.S. conceived and designed the experiments. R.Z. performed the experiments and acquired the data. J.W. and Q.W. contributed significantly to analysis and manuscript preparation. Y.L., Y.H. and X.L. performed the data analyses and wrote the manuscript. I.B. contributed essential materials for the experiment and contributed to modification of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University, and the methods were carried out in accordance with the approved guidelines. Written informed consent to participate was obtained for all participants (including all family members of this pedigree and 100 unrelated controls) before collecting blood samples.

**Consent for publication**

Written informed consent for the publication of this case report, any accompanying medical data and gene detection results was obtained from all participants or from the guardians of participants < 18 years old. A copy of the written consent is available for review by the journal editor. All authors have approved the publication of this manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Curatolo P, Mocarelo R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. The Lancet Neurology. 2015;14:733-45.
2. Morrison PJ. Tuberous sclerosis: epidemiology, genetics and progress towards treatment. Neuropediatrics. 2009;33:342–3.
3. Cino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–56.
4. Nellist M, Brouwer RW, Kokx CE, van Veghel-Plandoen M, Withagen-Hermans C, Prins-Bakker L, et al. Targeted next generation sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet. 2015;16:10.
5. Devlin LA, Shepherd C, Crawford H, Morrison PJ. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol. 2006;48:695–9.
6. de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics. 2010;7:275–82.
7. Sancak O, Nellist M, Goedbloed M, Efferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13:731–41.
8. Juelich K, Sahin M. Mechanism—based treatment in tuberous sclerosis complex. Pediatr Neurol. 2014;50:290–6.
9. Tyburczy ME, Wang JA, Li S, Thangapazham R, Chekaluk Y, Moss J, et al. Sun exposure causes somatic second-hit mutations and angioblastoma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23:2023–9.
10. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwon MH, et al. Analysis of chromosome 16p13 LAM1: Lymphangioleiomyomatosis; mTORC1: mechanistic target of rapamycin complex; Rheb: Ras homolog enriched in brain; TSC: Tuberous sclerosis complex

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Nephrology, the Affiliated Qingdao Municipal Hospital of Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, People’s Republic of China. 2Central Laboratory, the Affiliated Hospital of Qingdao University, Qingdao 266003, People’s Republic of China. 3Organ Transplantation Center, the Affiliated Hospital of Qingdao University, Qingdao 266003, People’s Republic of China. 4Department of Ophthalmology, the Affiliated Hospital of Qingdao University, Qingdao 266003, People’s Republic of China. 5Department of Radiology, the Affiliated Hospital of Qingdao University, Qingdao 266003, People’s Republic of China. 6Division of Medical Genetics, Department of Molecular Medicine, Sapienza University, San Camillo-Forlanini Hospital, 00185 Rome, Italy.

Received: 11 April 2018 Accepted: 12 September 2018

Published online: 20 September 2018
18. Jansen FE, Braams O, Vincken KL, Algra A, Anbeek P, Jennekens-Schinkel A, et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology. 2008;70:908–15.

19. Dombkowski AA, Batista CE, Cukovic D, Carruthers NJ, Ranganathan R, Shukla U, et al. Cortical tubers: windows into dysregulation of epilepsy risk and synaptic signaling genes by microRNAs. Cereb Cortex. 2016;26:1059–71.